骨显像与肿瘤标志物检测在89 SrCl2治疗晚期肺癌骨转移疗效评价中的价值

目的：探讨骨显像与几种常用肿瘤标记物检测在评价89 SrCl2治疗肺癌晚期骨转移疗效方面的价值。方法93例肺癌晚期骨转移患者在89 SrCl2治疗前、后分别行骨显像检查及肿瘤标记物(CYFRA21-1、NSE 和CEA)检测，并进行评价。结果在治疗后1 w、2 w、1个月和3个月，患者疼痛评分较治疗前明显下降(P <0.001)；骨显像示部分患者治疗后病灶缩小，甚至消失，有效率为70.97%；治疗前、后血清 CYFRA21-1、CEA 和NSE 水平比较，差异无统计学意义(P >0.05)。治疗后未出现严重毒副反应。结论骨显像可显示晚期肺癌骨转移在89 SrCl2治疗前、后病灶数目及大小变化；肿瘤标记物(CYFRA21-1、NSE 和 CEA)检测对评价89 SrCl2治疗肺癌晚期骨转移患者的疗效无明显意义。

The Value of Bone Imaging and Detection of Tumor Markers in the Therapeutic Efficacy Evaluation of 89 SrCl2 on Bone Metastases with Advanced Lung Cancer

Objective To explore the value of bone imaging and detection of the common tumor markers including CYFRA21-1,NSE and CEA in the therapeutic efficacy evaluation of 89 SrCl2 on the bone metastases with advanced lung cancer.Methods The bone imaging and detected tumor markers including CYFRA21-1,NSE and CEA were evaluated after 93 cases of bone metastases with advanced lung cancer were treated with 89 SrCl2 .Results There were significant differences in the pain score and the remission pain rate during the first week,the second week,the first month and the third month respectively (P <0.001).The bone imaging showed that some patients′tumor reduced and even disappeared,and the efficiency rate was 70.97%.There were no significant differences in the tumor markers including CYFRA21-1,NSE and CEA between before and after the treatment and no serious adverse effects after the treatment.Conclusion The bone imaging can show the nidus changes in numbers and sizes before and after the bone metastases with advanced lung cancer are treated with 89 SrCl2 on and the tumor markers including CYFRA21-1,NSE and CEA have no significance in evaluating the therapeutic efficacy of 89 SrCl2 on bone metastases with advanced lung cancer.